Zum Inhalt springen
| Eingeschlossene Patienten: 20.613 (Stand 1. Juli 2021) | |
| Amgevita® (Adalimumab) | 117 |
| Benepali® (Etanercept) | 797 |
| Cimzia® (Certolizumab) | 959 |
| Enbrel® (Etanercept) | 2866 |
| Erelzi® (Etanercept) | 361 |
| Flixabi® (Infliximab) | 9 |
| Hulio® (Adalimumab) | 78 |
| Humira® (Adalimumab) | 2903 |
| Hyrimoz® (Adalimumab) | 98 |
| Idacio® (Adalimumab) | 29 |
| Imraldi® (Adalimumab) | 126 |
| Inflectra™ (Infliximab) | 16 |
| Jyseleca® (Filgotinib) | 14 |
| Kevzara® (Sarilumab) | 163 |
| Kineret® (Anakinra) | 89 |
| MabThera® (Rituximab) | 1458 |
| Nepexto® (Etanercept) | 16 |
| Olumiant® (Baricitinib) | 452 |
| Orencia® (Abatacept) | 880 |
| Remicade® (Infliximab) | 762 |
| Remsima® (Infliximab) | 12 |
| Rinvoq® (Upadacitinib) | 161 |
| Rixathon® (Rituximab) | 16 |
| RoActemra® (Tocilizumab) | 1331 |
| Ruxience® (Rituximab) | 1 |
| Simponi® (Golimumab) | 449 |
| Xeljanz® (Tofacitinib) | 368 |
| Zessly® (Infliximab) | 2 |
| Kontrollen | 6080 |
